These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 18691133)

  • 21. The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.
    Shin E; Lisci C; Tronci E; Fidalgo C; Stancampiano R; Björklund A; Carta M
    Neurobiol Dis; 2014 Feb; 62():233-40. PubMed ID: 24135006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The dopamine D2 receptor agonist alpha-dihydroergocryptine modulates voltage-gated sodium channels in the rat caudate-putamen.
    Neusch C; Böhme V; Riesland N; Althaus M; Moser A
    J Neural Transm (Vienna); 2000; 107(5):531-41. PubMed ID: 11072749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease.
    Stoner SC; Dahmen MM; Makos M; Lea JW; Carver LJ; Rasu RS
    Ann Pharmacother; 2009 Sep; 43(9):1426-32. PubMed ID: 19690226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An in vivo pharmacological evaluation of pardoprunox (SLV308)--a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease.
    Jones CA; Johnston LC; Jackson MJ; Smith LA; van Scharrenburg G; Rose S; Jenner PG; McCreary AC
    Eur Neuropsychopharmacol; 2010 Aug; 20(8):582-93. PubMed ID: 20434890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dysbindin-1 modifies signaling and cellular localization of recombinant, human D₃ and D₂ receptors.
    Schmieg N; Rocchi C; Romeo S; Maggio R; Millan MJ; Mannoury la Cour C
    J Neurochem; 2016 Mar; 136(5):1037-51. PubMed ID: 26685100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PD 158771, a potential antipsychotic agent with D(2)/D(3) partial agonist and 5-HT(1A) agonist actions. I. Neurochemical effects.
    Akunne HC; Zoski KT; Davis MD; Cooke LW; Meltzer LT; Whetzel SZ; Shih YH; Wustrow DJ; Wise LD; MacKenzie RG; Georgic LM; Heffner TG; Pugsley TA
    Neuropharmacology; 2000 Apr; 39(7):1197-210. PubMed ID: 10760362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the dopamine D3 receptor: an overview of drug design strategies.
    Cortés A; Moreno E; Rodríguez-Ruiz M; Canela EI; Casadó V
    Expert Opin Drug Discov; 2016 Jul; 11(7):641-64. PubMed ID: 27135354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The group I metabotropic glutamate receptor antagonist S-4-CPG modulates the locomotor response produced by the activation of D1-like, but not D2-like, dopamine receptors in the rat nucleus accumbens.
    David HN; Abraini JH
    Eur J Neurosci; 2001 Jun; 13(11):2157-64. PubMed ID: 11422457
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High frequency electro-acupuncture enhances striatum DAT and D1 receptor expression, but decreases D2 receptor level in 6-OHDA lesioned rats.
    Rui G; Guangjian Z; Yong W; Jie F; Yanchao C; Xi J; Fen L
    Behav Brain Res; 2013 Jan; 237():263-9. PubMed ID: 23036843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bimodal induction of dopamine-mediated striatal neurotoxicity is mediated through both activation of D1 dopamine receptors and autoxidation.
    Wersinger C; Chen J; Sidhu A
    Mol Cell Neurosci; 2004 Jan; 25(1):124-37. PubMed ID: 14962746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopaminergic modulation of nitric oxide synthase activity in subregions of the rat nucleus accumbens.
    Hoque KE; West AR
    Synapse; 2012 Mar; 66(3):220-31. PubMed ID: 22034069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Native human neocortex release-regulating dopamine D2 type autoreceptors are dopamine D2 subtype.
    Fedele E; Fontana G; Munari C; Cossu M; Raiteri M
    Eur J Neurosci; 1999 Jul; 11(7):2351-8. PubMed ID: 10383624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduced basal and ethanol stimulation of striatal extracellular dopamine concentrations in dopamine D2 receptor knockout mice.
    Job MO; Ramachandra V; Anders S; Low MJ; Gonzales RA
    Synapse; 2006 Aug; 60(2):158-64. PubMed ID: 16715495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo dopamine agonist properties of rotigotine: Role of D1 and D2 receptors.
    Fenu S; Espa E; Pisanu A; Di Chiara G
    Eur J Pharmacol; 2016 Oct; 788():183-191. PubMed ID: 27343381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Receptor subtype-specific dopaminergic agents and unconditioned behavior.
    Beninger RJ; Mazurski EJ; Hoffman DC
    Pol J Pharmacol Pharm; 1991; 43(6):507-28. PubMed ID: 1687945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
    Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
    Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual ligands targeting dopamine D2 and serotonin 5-HT1A receptors as new antipsychotical or anti-Parkinsonian agents.
    Ye N; Song Z; Zhang A
    Curr Med Chem; 2014; 21(4):437-57. PubMed ID: 24164194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The roles of dopamine and serotonin, and of their receptors, in regulating sleep and waking.
    Monti JM; Jantos H
    Prog Brain Res; 2008; 172():625-46. PubMed ID: 18772053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential effect of quinpirole and 7-OH-DPAT on the spontaneous [(3)H]-dopamine efflux from rat striatal synaptosomes.
    García-Sanz A; Badia A; Clos MV
    Synapse; 2001 Apr; 40(1):65-73. PubMed ID: 11170223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopamine inhibits somatolactin gene expression in tilapia pituitary cells through the dopamine D2 receptors.
    Jiang Q; Lian A; He Q
    Comp Biochem Physiol A Mol Integr Physiol; 2016 Jul; 197():35-42. PubMed ID: 26970582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.